3SBIO (01530.HK) stock is soaring 5.19% in pre-market trading on Wednesday, following the company's announcement of robust financial results for the fiscal year and a final dividend declaration.

The Chinese biopharmaceutical company reported impressive financial metrics, including revenue of RMB 9,108 million and a gross profit of RMB 7,828.4 million. The company maintained a high gross margin of 86%, demonstrating strong operational efficiency. 3SBIO's EBITDA reached RMB 3,173.8 million, with adjusted EBITDA slightly higher at RMB 3,402.3 million. The company also posted a basic earnings per share (EPS) of RMB 0.86.

Investors are particularly encouraged by 3SBIO's announcement of a final dividend of HKD25 cents per share, signaling confidence in the company's financial health and commitment to shareholder returns. This combination of strong financial performance and generous dividend payout appears to be driving the significant pre-market surge in 3SBIO's stock price.